An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial

The efficacy of immune checkpoint inhibitors has been shown to depend on preexisting antitumor immunity; thus, their combination with cancer vaccines is an attractive therapeutic approach. Plasmacytoid dendritic cells (PDC) are strong inducers of antitumor responses and represent promising vaccine c...

Descripción completa

Detalles Bibliográficos
Autores principales: Charles, Julie, Chaperot, Laurence, Hannani, Dalil, Bruder Costa, Juliana, Templier, Isabelle, Trabelsi, Sabiha, Gil, Hugo, Moisan, Anaick, Persoons, Virginie, Hegelhofer, Harald, Schir, Edith, Quesada, Jean-Louis, Mendoza, Christophe, Aspord, Caroline, Manches, Olivier, Coulie, Pierre G., Khammari, Amir, Dreno, Brigitte, Leccia, Marie-Thérèse, Plumas, Joel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153838/
https://www.ncbi.nlm.nih.gov/pubmed/32313721
http://dx.doi.org/10.1080/2162402X.2020.1738812

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153838/
https://www.ncbi.nlm.nih.gov/pubmed/32313721
http://dx.doi.org/10.1080/2162402X.2020.1738812

Ejemplares similares